Eyepoint Pharmaceuticals will participate in the ASRS 44th Annual Meeting in Montreal to engage the retina community and explore strategies to advance treatments and improve patient outcomes.
The company plans to connect with industry professionals to exchange ideas and collaborate on initiatives that the company presents as pushing the boundaries of current retina care practices.
Eyepoint has previously urged early detection for wet age-related macular degeneration because symptoms can progress rapidly and continues to promote its clinical trial program.
The firm is also slated to present new research in retinal disease treatment at CTS Retina 2026 in Las Vegas, reflecting ongoing engagement with developments in retinal science.
Source: https://tradersunion.com/news/companies/show/2595379-eyepoint-pharma-asrs-meeting/
